{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:42:56Z","timestamp":1791934976396,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","award":["59-053"],"award-info":[{"award-number":["59-053"]}],"id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heart Association of Thailand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to investigate the relationship between time in target range of systolic blood pressure (SBP-TTr) and clinical outcomes in patients with atrial fibrillation (AF). We analyzed the results from multicenter AF registry in Thailand. Blood pressure was recorded at baseline and at every 6 monthly follow-up visit. SBP-TTr were calculated using the Rosendaal method, based on a target SBP 120\u2013140\u00a0mmHg. The outcomes were death, ischemic stroke\/systemic embolism (SSE), major bleeding, and heart failure. A total of 3355 patients were studied (mean age 67.8\u00a0years; 41.9% female). Average follow-up time was 32.1\u2009\u00b1\u20098.3\u00a0months. SBP-TTr was classified into 3 groups according to the tertiles. The incidence rates of all-cause death, SSE, major bleeding, and heart failure were 3.90 (3.51\u20134.34), 1.52 (1.27\u20131.80), 2.2 (1.90\u20132.53), and 2.83 (2.49\u20133.21) per 100 person-years, respectively. Patients in the 3rd tertile of SBP-TTr had lower rates of death, major bleeding and heart failure with adjusted hazard ratios 0.62 (0.48\u20130.80), p\u2009&lt;\u20090.001, 0.64 (0.44\u20130.92), p\u2009=\u20090.016, and 0.61 (0.44\u20130.84), p\u2009=\u20090.003, respectively, compared to 1st SBP-TTr tertile. In conclusion, high SBP-TTr was associated with better clinical outcomes compared to other groups with lower SBP-TTr. This underscores the importance of good blood pressure control in AF patients.<\/jats:p>","DOI":"10.1038\/s41598-024-51385-0","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T13:02:50Z","timestamp":1704718970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Time in target range of systolic blood pressure and clinical outcomes in atrial fibrillation patients: results of the COOL-AF registry"],"prefix":"10.1038","volume":"14","author":[{"given":"Rungroj","family":"Krittayaphong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ply","family":"Chichareon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chulalak","family":"Komoltri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahthit","family":"Yindeengam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"51385_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/CIA.S302389","volume":"16","author":"R Krittayaphong","year":"2021","unstructured":"Krittayaphong, R., Boonyapiphat, T., Wongvipaporn, C., Sairat, P. & Investigators, C.-A. Age-related clinical outcomes of patients with non-valvular atrial fibrillation: Insights from the COOL-AF registry. Clin. Interv. Aging 16, 707\u2013719. https:\/\/doi.org\/10.2147\/CIA.S302389 (2021).","journal-title":"Clin. Interv. Aging"},{"key":"51385_CR2","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","volume":"37","author":"JP Bassand","year":"2016","unstructured":"Bassand, J. P. et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Eur. Heart J. 37, 2882\u20132889. https:\/\/doi.org\/10.1093\/eurheartj\/ehw233 (2016).","journal-title":"Eur. Heart J."},{"key":"51385_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026410","volume":"11","author":"WY Ding","year":"2022","unstructured":"Ding, W. Y. et al. Incidence and risk factors for residual adverse events despite anticoagulation in atrial fibrillation: Results from phase II\/III of the GLORIA-AF registry. J. Am. Heart Assoc. 11, e026410. https:\/\/doi.org\/10.1161\/JAHA.122.026410 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"51385_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip, G. Y. H. The ABC pathway: An integrated approach to improve AF management. Nat. Rev. Cardiol. 14, 627\u2013628. https:\/\/doi.org\/10.1038\/nrcardio.2017.153 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"51385_CR5","doi-asserted-by":"publisher","DOI":"10.1055\/a-1515-9630","author":"GF Romiti","year":"2021","unstructured":"Romiti, G. F. et al. Adherence to the \u201catrial fibrillation better care\u201d pathway in patients with atrial fibrillation: Impact on clinical outcomes\u2014A systematic review and meta-analysis of 285,000 patients. Thromb. Haemost. https:\/\/doi.org\/10.1055\/a-1515-9630 (2021).","journal-title":"Thromb. Haemost."},{"key":"51385_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/europace\/euaa274","volume":"23","author":"M Proietti","year":"2021","unstructured":"Proietti, M. et al. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: An analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Europace 23, 174\u2013183. https:\/\/doi.org\/10.1093\/europace\/euaa274 (2021).","journal-title":"Europace"},{"key":"51385_CR7","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1055\/s-0039-1693516","volume":"119","author":"M Yoon","year":"2019","unstructured":"Yoon, M. et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care management: A nationwide cohort study. Thromb. Haemost. 119, 1695\u20131703. https:\/\/doi.org\/10.1055\/s-0039-1693516 (2019).","journal-title":"Thromb. Haemost."},{"key":"51385_CR8","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jacc.2020.01.052","volume":"75","author":"Y Guo","year":"2020","unstructured":"Guo, Y. et al. Mobile health technology to improve care for patients with atrial fibrillation. J. Am. Coll. Cardiol. 75, 1523\u20131534. https:\/\/doi.org\/10.1016\/j.jacc.2020.01.052 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"51385_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks, G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 42, 373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612 (2020).","journal-title":"Eur. Heart J."},{"key":"51385_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0041-1739411","volume":"122","author":"TF Chao","year":"2022","unstructured":"Chao, T. F. et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: Executive summary. Thromb. Haemost. 122, 20\u201347. https:\/\/doi.org\/10.1055\/s-0041-1739411 (2022).","journal-title":"Thromb. Haemost."},{"key":"51385_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip, G. Y. H. et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 154, 1121\u20131201. https:\/\/doi.org\/10.1016\/j.chest.2018.07.040 (2018).","journal-title":"Chest"},{"key":"51385_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12872-018-0911-4","volume":"18","author":"R Krittayaphong","year":"2018","unstructured":"Krittayaphong, R. et al. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: A multicenter study. BMC Cardiovasc. Disord. 18, 174. https:\/\/doi.org\/10.1186\/s12872-018-0911-4 (2018).","journal-title":"BMC Cardiovasc. Disord."},{"key":"51385_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063479","volume":"8","author":"AK Kakkar","year":"2013","unstructured":"Kakkar, A. K. et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Perspectives from the international, observational, prospective GARFIELD registry. PLoS\u00a0One 8, e63479. https:\/\/doi.org\/10.1371\/journal.pone.0063479 (2013).","journal-title":"PLoS\u00a0One"},{"key":"51385_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1093\/eurheartj\/ehy877","volume":"40","author":"TH Kim","year":"2019","unstructured":"Kim, T. H. et al. Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: Nationwide data covering the entire Korean population. Eur. Heart J. 40, 809\u2013819. https:\/\/doi.org\/10.1093\/eurheartj\/ehy877 (2019).","journal-title":"Eur. Heart J."},{"key":"51385_CR15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/ajh\/hpx094","volume":"30","author":"M Ishii","year":"2017","unstructured":"Ishii, M. et al. Relationship of hypertension and systolic blood pressure with the risk of stroke or bleeding in patients with atrial fibrillation: The Fushimi AF Registry. Am. J. Hypertens. 30, 1073\u20131082. https:\/\/doi.org\/10.1093\/ajh\/hpx094 (2017).","journal-title":"Am. J. Hypertens."},{"key":"51385_CR16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.2147\/CIA.S335321","volume":"16","author":"R Krittayaphong","year":"2021","unstructured":"Krittayaphong, R. et al. Average systolic blood pressure and clinical outcomes in patients with atrial fibrillation: Prospective data from COOL-AF Registry. Clin. Interv. Aging 16, 1835\u20131846. https:\/\/doi.org\/10.2147\/CIA.S335321 (2021).","journal-title":"Clin. Interv. Aging"},{"key":"51385_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jacc.2018.05.076","volume":"72","author":"D Kim","year":"2018","unstructured":"Kim, D. et al. Ideal blood pressure in patients with atrial fibrillation. J. Am. Coll. Cardiol. 72, 1233\u20131245. https:\/\/doi.org\/10.1016\/j.jacc.2018.05.076 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"51385_CR18","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/s0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903\u20131913. https:\/\/doi.org\/10.1016\/s0140-6736(02)11911-8 (2002).","journal-title":"Lancet"},{"key":"51385_CR19","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"Blood Pressure Lowering Treatment Trialists Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: An individual participant-level data meta-analysis. Lancet 398, 1053\u20131064. https:\/\/doi.org\/10.1016\/S0140-6736(21)01921-8 (2021).","journal-title":"Lancet"},{"key":"51385_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCDRF Collaboration","year":"2021","unstructured":"NCDRF Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398, 957\u2013980. https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1 (2021).","journal-title":"Lancet"},{"key":"51385_CR21","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","volume":"388","author":"E Vidal-Petiot","year":"2016","unstructured":"Vidal-Petiot, E. et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: An international cohort study. Lancet 388, 2142\u20132152. https:\/\/doi.org\/10.1016\/S0140-6736(16)31326-5 (2016).","journal-title":"Lancet"},{"key":"51385_CR22","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"ACCORD Study Group","year":"2010","unstructured":"ACCORD Study Group et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575\u20131585. https:\/\/doi.org\/10.1056\/NEJMoa1001286 (2010).","journal-title":"N. Engl. J. Med."},{"key":"51385_CR23","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"SPRINT Study Group","year":"2015","unstructured":"SPRINT Study Group et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103\u20132116. https:\/\/doi.org\/10.1056\/NEJMoa1511939 (2015).","journal-title":"N. Engl. J. Med."},{"key":"51385_CR24","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339 (2018).","journal-title":"Eur. Heart J."},{"key":"51385_CR25","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton, P. K. et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 71, e127\u2013e248. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.006 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"51385_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. & Briet, E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 69, 236\u2013239 (1993).","journal-title":"Thromb. Haemost."},{"key":"51385_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/00015385.2021.1882111","volume":"77","author":"RE Harskamp","year":"2022","unstructured":"Harskamp, R. E. et al. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: A meta-analysis of randomised controlled trials. Acta Cardiol. 77, 191\u2013195. https:\/\/doi.org\/10.1080\/00015385.2021.1882111 (2022).","journal-title":"Acta Cardiol."},{"key":"51385_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40885-019-0132-x","volume":"26","author":"GC Oh","year":"2020","unstructured":"Oh, G. C. & Cho, H. J. Blood pressure and heart failure. Clin. Hypertens. 26, 1. https:\/\/doi.org\/10.1186\/s40885-019-0132-x (2020).","journal-title":"Clin. Hypertens."},{"key":"51385_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jchf.2017.08.015","volume":"5","author":"SE Lee","year":"2017","unstructured":"Lee, S. E. et al. Reverse J-curve relationship between on-treatment blood pressure and mortality in patients with heart failure. JACC Heart Fail. 5, 810\u2013819. https:\/\/doi.org\/10.1016\/j.jchf.2017.08.015 (2017).","journal-title":"JACC Heart Fail."},{"key":"51385_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41371-018-0153-z","volume":"33","author":"CE Clark","year":"2019","unstructured":"Clark, C. E., McDonagh, S. T. J. & McManus, R. J. Accuracy of automated blood pressure measurements in the presence of atrial fibrillation: Systematic review and meta-analysis. J. Hum. Hypertens. 33, 352\u2013364. https:\/\/doi.org\/10.1038\/s41371-018-0153-z (2019).","journal-title":"J. Hum. Hypertens."},{"key":"51385_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/HYPERTENSIONAHA.113.01426","volume":"62","author":"N Pagonas","year":"2013","unstructured":"Pagonas, N. et al. Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. Hypertension 62, 579\u2013584. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01426 (2013).","journal-title":"Hypertension"},{"key":"51385_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 137, 263\u2013272. https:\/\/doi.org\/10.1378\/chest.09-1584 (2010).","journal-title":"Chest"},{"key":"51385_CR33","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters, R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 138, 1093\u20131100. https:\/\/doi.org\/10.1378\/chest.10-0134 (2010).","journal-title":"Chest"},{"key":"51385_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2018.10.069","volume":"73","author":"P Muntner","year":"2019","unstructured":"Muntner, P. et al. Blood pressure assessment in adults in clinical practice and clinic-based research: JACC Scientific Expert Panel. J. Am. Coll. Cardiol. 73, 317\u2013335. https:\/\/doi.org\/10.1016\/j.jacc.2018.10.069 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"51385_CR35","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman, S., Kearon, C., Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3, 692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x (2005).","journal-title":"J. Thromb. Haemost."},{"key":"51385_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"KA Hicks","year":"2015","unstructured":"Hicks, K. A. et al. 2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J. Am. Coll. Cardiol. 66, 403\u2013469. https:\/\/doi.org\/10.1016\/j.jacc.2014.12.018 (2015).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51385-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51385-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51385-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T13:03:07Z","timestamp":1704718987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51385-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51385"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51385-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GYHL: Consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Anthos and Daiichi-Sankyo. No fees are directly received personally. GYHL is co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 899871. Other authors hereby declare no personal or professional conflicts of interest relating to any aspect of this particular study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"805"}}